Back to EveryPatent.com
| United States Patent |
5,334,607
|
|
Sauter
, et al.
|
August 2, 1994
|
Methods for treating mycoses
Abstract
Antimycotics containing a compound of the formula
##STR1##
where .dbd.Y is .dbd.CH--OCH.sub.3, .dbd.CH--CH.sub.3, .dbd.CH--CH.sub.2
--CH.sub.3, .dbd.CH--SCH.sub.3 or .dbd.N--OCH.sub.3, and X is oxygen, or X
may also be NH if Y is .dbd.N--OCH.sub.3,
Z is halogen, nitro, cyano, unsubstituted or substituted organic radicals,
OR.sup.12, SR.sup.13, SOR.sup.14, SO.sub.2 R.sup.15, --COOR.sup.16,
--CONR.sup.17 R.sup.18, --COR.sup.19, --CR.sup.20 .dbd.NR.sup.21,
--N.dbd.CR.sup.22 R.sup.23, --CR.sup.24 .dbd.N--OR.sup.25, --CR.sup.25
R.sup.26 --O--N.dbd.CR.sup.27 R.sup.28 and
U, V, W can be hydrogen or one of the meanings given for Z, or where two of
Z, U, V and W in adjacent positions on the phenyl ring can form an
unsubstituted or substituted five- or six-membered, aromatic or aliphatic
ring which may contain one to three hetero atoms (N, S, O), and R.sup.12
to R.sup.26 are identical or different and are hydrogen, unsubstituted or
substituted organic radicals,
are used for controlling mycoses.
| Inventors:
|
Sauter; Hubert (Mannheim, DE);
Lorenz; Gisela (Neustadt, DE);
Steiner; Gerd (Kirchheim, DE);
Janssen; Bernd (Ludwigshafen, DE);
Anke; Timm (Kaiserslautern, DE);
Steglich; Wolfgang (Munich, DE)
|
| Assignee:
|
BASF Aktiengesellschaft (Ludwigshafen, DE)
|
| Appl. No.:
|
889418 |
| Filed:
|
May 28, 1992 |
Foreign Application Priority Data
| Current U.S. Class: |
514/378; 514/267; 514/348; 514/403; 514/406; 514/522; 514/531; 514/532; 514/538; 514/617; 514/619; 514/626; 548/247; 560/35; 560/52; 560/55; 560/60 |
| Intern'l Class: |
A01N 037/10; A01N 037/50; A01N 043/40; A01N 043/54; A01N 043/56 |
| Field of Search: |
560/35
548/247
514/378,522,538,,531,532,348,619,403,406,267,617,626
|
References Cited
U.S. Patent Documents
| 3826836 | Jul., 1974 | Buchel et al. | 424/273.
|
| 4937372 | Jun., 1990 | Wenderoth et al. | 560/55.
|
| 4999042 | Mar., 1991 | Anthony et al. | 560/35.
|
| 5003101 | Mar., 1991 | Brand et al. | 560/55.
|
| 5021581 | Jun., 1991 | Clough et al. | 546/309.
|
| 5041618 | Aug., 1991 | Brand et al. | 560/104.
|
| 5051447 | Sep., 1991 | Wenderoth et al. | 514/534.
|
| 5112862 | May., 1991 | Wenderoth et al. | 514/522.
|
| Foreign Patent Documents |
| 0253213 | Jan., 1988 | EP | 560/35.
|
| 2172595 | Sep., 1986 | GB | 560/60.
|
| 2192883 | Jan., 1988 | GB | 560/35.
|
Other References
Godfrey et al., Chemical Abstracts, vol. 109, No. 110417t (1988).
|
Primary Examiner: Higel; Floyd D.
Attorney, Agent or Firm: Oblon, Spivak, McClelland, Maier & Neustadt
Claims
We claim:
1. A process for treating mycoses in humans and nonhuman animals comprising
administering a composition comprising an effective amount of an active
compound of the formula
##STR29##
where .dbd.Y is .dbd.CH--OCH.sub.3, .dbd.CH--CH.sub.3, .dbd.CH--CH.sub.2
--CH.sub.3, .dbd.CH--SCH.sub.3, or .dbd.N--OCH.sub.3 ; X is oxygen, or if
Y is .dbd.N--OCH.sub.3, also NH; Z is F, Cl, Br, I, nitro, cyano,
--OR.sup.12, --SR.sup.13, --SOR.sup.14, SO.sub.2 R.sup.15, --COOR.sup.16,
--CONR.sup.17 R.sup.18, --COR.sup.19, --CR.sup.20 .dbd.NR.sup.21,
--N.dbd.CR.sup.22 R.sup.23, --CR.sup.24 .dbd.N--OR.sup.25, --CR.sup.25
R.sup.26 --O--N.dbd.CR.sup.27 R.sup.28, --CR.sup.30 .dbd.CR.sup.31
R.sup.29, --CHR.sup.30 --CHR.sup.31 R.sup.29, --O--CHR.sup.30 R.sup.29,
--CHR.sup.30 --OR.sup.29, --CHR.sup.30 --SR.sup.29, --S--CHR.sup.30
R.sup.29, --O--N.dbd.CR.sup.30 R.sup.29, --CHR.sup.30 R.sup.29 ; or
--R.sup.31 CH--O--N.dbd.CR.sup.33 R.sup.32 ;
R.sup.12 to R.sup.29, identical or different, are hydrogen; C.sub.1-18
alkyl; C.sub.2-8 alkenyl; C.sub.2-8 alkynyl; a five- or six-membered
hetaryl with 1 to 3 atoms selected from the group consisting of N, O and
S; a five- or six-membered aryl which can be unsubstituted or substituted
1 or more times with halogen C.sub.1-12 alkyl, C.sub.1-12 haloalkyl,
C.sub.2-12 alkenyl, C.sub.2-12 alkynyl, C.sub.1-12 alkoxy, C.sub.1-12
haloalkoxy, C.sub.2-12 alkenyloxy, C.sub.2-12 alkynyloxy, formyl,
C.sub.1-12 acyl, cyano, trifluoromethyl, nitro or --CR.sup.40
.dbd.N--OR.sup.41 where R.sup.40 is H or C.sub.1-4 alkyl and R.sup.41 is
H, C.sub.1-8 alkyl, C.sub.2-8 alkenyl, or C.sub.2-8 alkynyl;
R.sup.30 and R.sup.31, identical or different, are H or a straight chain or
branched C.sub.1-4 alkyl;
R.sup.32 and R.sup.33, the same or different, are H, C.sub.1-12 alkyl,
C.sub.1-4 haloalkyl, C.sub.1-4 alkoxy-C.sub.1-4 alkyl, C.sub.1-4
haloalkyl, C.sub.1-4 alkoxy-C.sub.1-4 -alkyl, aryloxy-C.sub.1-4 alkyl,
arylthio C.sub.1-4 alkenyl, hetaryl-C.sub.2-4 alkenyl, C.sub.2-12
-alkynyl, C.sub.3-6 -cycloalkyl, aryl, hetaryl, cyano, --COOR.sup.34,
--CONR.sup.35 R.sup.36, --COR.sup.37, --CR.sup.38 --NOR.sup.39 or R.sup.32
and R.sup.33 form, together with the carbon atom to which they are bonded,
a 4- or 7-membered ring which can contain an oxygen or sulfur atom;
R.sup.34 to R.sup.39 are H, C.sub.1-4 alkyl, aryl or hetaryl;
wherein said aryl is a five- or six-membered ring which is unsubstituted or
substituted 1 or more times with halogen, C.sub.1-12 alkyl, C.sub.1-12
haloalkyl, C.sub.2-12 alkenyl, C.sub.2-12 alkynyl, C.sub.1-12 alkoxy,
C.sub.1-12 haloalkoxy, C.sub.2-12 alkenyloxy, C.sub.2-12 alkynyloxy,
formyl, C.sub.1-12 acyl, cyano, trifluoromethyl, nitro or --CR.sup.40
.dbd.N--OR.sup.41 where R.sup.40 is H or C.sub.1-4 alkyl and R.sup.41 is
H, C.sub.1-8 alkyl C.sub.2-8 alkenyl or C.sub.2-8 alkynyl; and
said hetaryl is a five- or six-membered ring with 1 to 3 atoms selected
from the group consisting of N, O and S.
2. The process according to claim 1, wherein said composition further
comprises a solid, semi-solid or liquid excipient or diluent.
3. The process according to claim 1, wherein said active compound is
administered in an amount of from about 1.0 to about 50.0 mg/kg of body
weight per day.
4. The process according to claim 1, wherein 0.01 to 90% by weight, based
on the total weight of the composition, of said active compound is present
in said composition.
5. A process for treating mycoses in humans and nonhuman animals comprising
administering a composition comprising an effective amount of an active
compound of the formula
##STR30##
where .dbd.Y is .dbd.CH--OCH.sub.3, .dbd.CH--CH.sub.3, .dbd.CH--CH.sub.2
--CH.sub.3, .dbd.CH--SCH.sub.3, or .dbd.N--OCH.sub.3 ;
X is oxygen, or if Y is .dbd.N--OCH.sub.3, also NH:
Z is
##STR31##
6. The process according to claim 5, wherein Z is
##STR32##
Y is .dbd.CH--OCH.sub.3, and X is O.
Description
The present invention relates to antimycotics which contain phenylacetic
acid derivatives and to the use of these derivatives as antimycotics.
The use of phenylacetic acid derivatives as fungicides in crop protection
has been disclosed (EP 178 826, 203 606, 203 608, 226 917, 229 974, 242
070, 242 081, 244 077, 251 082, 253 213, 254 426, 256 667, 260 794, 267
734, 270 252, 278 595, 280 185, 291 196, 299 694, 307 103, 310 954, 336
211, 337 211, 341 845, 342 459, 350 691, 354 571, 363 818, 370 629, 374
811, 378 308, 378 755, 379 098, 382 375, 385 224, 385 357, 386 561, 393
428, 393 861, 398 692, 400 417, 405 782, 422 597, 426 460, 459 285, 460
575, 463 488, 468 684, 468 695 and 468 775). There is no indication of an
antimycotic action therein.
We have now found that compounds of the formula
##STR2##
where
.dbd.Y is .dbd.CH--OCH.sub.3, .dbd.CH--CH.sub.3, .dbd.CH--CH.sub.2
--CH.sub.3, .dbd.CH--SCH.sub.3 or .dbd.N--OCH.sub.3,
X is oxygen or, if Y is .dbd.N--OCH.sub.3, also NH,
Z is halogen (F, Cl, Br, I), nitro, cyano, unsubstituted or substituted
alkyl, unsubstituted or substituted cycloalkyl, unsubstituted or
substituted aralkyl, unsubstituted or substituted aryloxyalkyl,
unsubstituted or substituted arylthioalkyl, unsubstituted or substituted
hetarylalkyl, unsubstituted or substituted hetaryloxyalkyl, unsubstituted
or substituted hetarylthioalkyl, unsubstituted or substituted alkenyl,
unsubstituted or substituted aralkenyl, unsubstituted or substituted
aryloxyalkenyl, unsubstituted or substituted arylthioalkenyl,
unsubstituted or substituted hetarylalkenyl, unsubstituted or substituted
hetaryloxyalkenyl, unsubstituted or substituted hetarylthioalkenyl,
unsubstituted or substituted alkynyl, unsubstituted or substituted aryl,
unsubstituted or substituted hetaryl, unsubstituted or substituted amino,
unsubstituted or substituted arylazo, unsubstituted or substituted
acylamino, OR.sup.12, SR.sup.13, SOR.sup.14, SO.sub.2 R.sup.15,
--COOR.sup.16, --CONR.sup.17 R.sup.18, --COR.sup.19, --CR.sup.20
.dbd.NR.sup.21, --N.dbd.CR.sup.22 R.sup.23, --CR.sup.24 .dbd.N--OR.sup.25,
--CR.sup.25 R.sup.26 --O--N.dbd.CR.sup.27 R.sup.28 and
U, V, W are identical or different and can be hydrogen or one of the
meanings given for Z, or where two of Z, U, V and W in adjacent positions
on the phenyl ring can form an unsubstituted or substituted five- or
six-membered, aromatic or aliphatic ring which may contain one to three
hetero atoms (N, S, O), and R.sup.12 to R.sup.28 are identical or
different and are hydrogen, unsubstituted or substituted C.sub.1 -C.sub.8
-alkyl, unsubstituted or substituted C.sub.2 -C.sub.8 -alkenyl,
unsubstituted or substituted C.sub.2 -C.sub.8 -alkynyl, unsubstituted or
substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl,
unsubstituted or substituted aryl, unsubstituted or substituted hetaryl,
unsubstituted or substituted aralkyl, unsubstituted or substituted
hetarylalkyl, unsubstituted or substituted aryloxyalkyl, unsubstituted or
substituted arylthioalkyl, unsubstituted or substituted hetaryloxyalkyl or
unsubstituted or substituted hetarylthioalkyl,
have a good antimycotic action. The compounds and the preparation thereof
have been disclosed (see the European Laid-Open Applications mentioned at
the outset).
One aspect of the invention relates to antimycotics which contain compounds
of the formula 1 where U, V and W are identical or different and are
hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro,
trifluoromethyl, methyl or methoxy.
Another aspect of the invention relates to antimycotics which contain
compounds of the formula 1 where U, V and W are hydrogen.
Another aspect of the invention relates to antimycotics which contain
compounds of the formula 1 where Z is OR.sup.12 or SR.sup.13, and R.sup.12
and R.sup.13 have the abovementioned meanings.
Another aspect of the invention relates to antimycotics which contain
compounds of the formula 1 where R.sup.12 and R.sup.13 are unsubstituted
or substituted alkyl, unsubstituted or substituted aryl, or unsubstituted
or substituted five- or six-membered hetaryl with 1 to 3 hetero atoms (N,
O, S).
Another aspect of the invention relates to antimycotics which contain
compounds of the formula 1a
##STR3##
where U, V, W, X and Y have the abovementioned meanings, and --A-- is
--CR.sup.30 .dbd.CR.sup.31 --, --CHR.sup.+ --CHR.sup.31 --,
--O--CHR.sup.30 --, --CHR.sup.+ --O--, --CHR.sup.30 --S--, --S--CHR.sup.30
--, --O--N.dbd.CR.sup.30 -- or --CHR.sup.30 --, and where R.sup.29 is
unsubstituted or substituted alkyl, unsubstituted or substituted alkenyl,
unsubstituted or substituted aryl, unsubstituted or substituted hetaryl,
unsubstituted or substituted aralkyl, unsubstituted or substituted
hetarylalkyl, and R.sup.30 and R.sup.31 are identical or different and are
hydrogen or straight-chain or branched C.sub.1 -C.sub.4 -alkyl.
Another aspect of the invention relates to antimycotics which contain
compounds of the formula 1a where R.sup.29 --A-- is R.sup.32 R.sup.33
C.dbd.N--O--CHR.sup.31 -- where R.sup.31 has the abovementioned meanings,
and R.sup.32 and R.sup.33 are, independently of one another, hydrogen,
C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.4 -haloalkyl, C.sub.1 -C.sub.4
-alkoxy-C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.12 -alkylthio-C.sub.1
-C.sub.4 -alkyl, aryl-C.sub.1 -C.sub.4 -alkyl, aryloxy-C.sub.1 -C.sub.4
-alkyl, arylthio-C.sub.1 --C.sub.4 -alkyl, hetaryl-C.sub.1 -C.sub.4
-alkyl, C.sub.2 -C.sub.12 -alkenyl, aryl-C.sub.2 -C.sub.4 -alkenyl,
hetaryl-C.sub.2 -C.sub.4 -alkenyl, C.sub.2 -C.sub.12 -alkynyl, C.sub.3
-C.sub.6 -cycloalkyl, aryl, hetaryl, cyano or one of (a) to (d)
##STR4##
or R.sup.32 and R.sup.33 form, together with the carbon atom to which they
are bonded, a 4- to 7-membered ring which may contain an oxygen or sulfur
atom and which may have one or two aromatic rings fused on, e.g.
unsubstituted or substituted benzene rings, and R.sup.34, R.sup.35,
R.sup.36, R.sup.37, R.sup.38 and R.sup.39 are each hydrogen, C.sub.1
-C.sub.4 -alkyl, aryl or hetaryl.
Another aspect of the invention relates to antimycotics which contain
compounds of the formula 1a where R.sup.29 is five- or six-membered aryl
which is unsubstituted or substituted one or more times by halogen,
C.sub.1 -C.sub.12 -alkyl, C.sub.1 -C.sub.12 -haloalkyl, C.sub.2 -C.sub.12
-alkenyl, C.sub.2 -C.sub.12 -alkynyl, unsubstituted or substituted aryl,
unsubstituted or substituted hetaryl, unsubstituted or substituted
aralkyl, C.sub.1 -C.sub.12 -alkoxy, C.sub.1 -C.sub.12 -haloalkoxy, C.sub.2
-C.sub.12 -alkenyloxy, C.sub.2 -C.sub.12 -alkynyloxy, unsubstituted or
substituted aryloxy, formyl, C.sub.1 -C.sub.12 -acyl, cyano,
trifluoromethyl, nitro or --CR.sup.34 .dbd.N--OR.sup.35 and/or may be
fused with a benzene ring, or is benzyl or hetaryl, where R.sup.34 is
hydrogen or C.sub.1 -C.sub.4 -alkyl and R.sup.35 is hydrogen, C.sub.1
-C.sub.8 -alkyl, C.sub.2 -C.sub.8 -alkenyl or C.sub.2 -C.sub.8 -alkynyl.
Supplementary reference is made, concerning the preparation of the active
substances, to the fact that the compounds where Y has any of the
abovementioned meanings can be prepared from the keto esters of the
formula 2
##STR5##
where U, V, W, X and Z have the abovementioned meanings, by known
processes.
Furthermore, the preparation of the keto esters 2 is described in the
abovementioned publications.
Examples of compounds of the formula I which can be present in the
antimycotics according to the invention are listed in Table 1. Other
examples are indicated in the European patent applications mentioned.
##STR6##
The compounds may occur in isomeric forms in respect of the C.dbd.Y double
bond. The E isomers are preferred.
TABLE 1
__________________________________________________________________________
No.
Z U, V, W
Y X
__________________________________________________________________________
1
##STR7## H, H, H
CHOCH.sub.3 (E)
O
2
##STR8## " NOCH.sub.3 (E)
O
3 " " CHCH.sub.3 (E)
O
4 " " CHCH.sub.2CH.sub.3 (E)
O
5 " " CHSCH.sub.3 (E)
O
6 " " NOCH.sub.3 (E)
NH
7
##STR9## " CHOCH.sub.3 (E)
O
8
##STR10## " NOCH.sub.3 (E)
O
9
##STR11## " NOCH.sub.3 (E)
O
10 " " CHOCH.sub.3 (E)
O
11
##STR12## " NOCH.sub.3 (E)
O
12 " " CHOCH.sub.3 (E)
O
13
##STR13## " CHOCH.sub.3 (E)
O
14
##STR14## H, H, H
CHOCH.sub.3 (E)
O
15 " " NOCH.sub.3 (E)
O
16
##STR15## " CHOCH.sub.3 (E)
O
17
##STR16## " CHOCH.sub.3 (E)
O
18
##STR17## " NOCH.sub.3 (E)
O
19 " " CHOCH.sub.3 (E)
O
20
##STR18## " NOCH.sub.3 (E)
O
21 " " " NH
22
##STR19## " " O
23 " " " NH
24
##STR20## " CHOCH.sub.3 (E)
O
25 " " CHCH.sub.3 (E)
O
26 " " CHCH.sub.2CH.sub.3 (E)
O
27 " " NOCH.sub.3 (E)
O
28
##STR21## " CHOCH.sub.3 (E)
O
29 " " NOCH.sub.3 (E)
O
30
##STR22## " CHOCH.sub.3 (E)
O
31 " " NOCH.sub.3 (E)
O
32
##STR23## " CHOCH.sub.3 (E)
O
33
##STR24## " NOCH.sub.3 (E)
O
34
##STR25## " NOCH.sub.3 (E)
O
35
##STR26## " NOCH.sub.3 (E)
O
36
##STR27## " CHOCH.sub.3 (E)
O
37
##STR28## " NOCH.sub.3 (E)
O
__________________________________________________________________________
Surprisingly, the phenylacetic acid derivatives not only have a very good
in vitro antimycotic activity but also a good in vivo activity which can
be used therapeutically, especially for dermatophytes, but also for other
microorganisms. They also have antibacterial activity. The active
substances thus represent a valuable enrichment of pharmacy.
The action on dermatophytes, bacteria and protozoa can be demonstrated by
methods as are described, for example, in P. Klein, Bakteriologische
Grundlagen der chemotherapeutischen Laboratoriumspraxis, SpringerVerlag,
Berlin, 1957. The action on yeasts can be demonstrated in the test on the
pseudomycelium or mycelium phase (cf. DE-A 30 20 093).
The minimum inhibitory concentration (MIC) was determined by the agar
dilution method of DIN 58 940/ICS.
For this, Petri dishes with a diameter of 9 cm were charged under sterile
conditions with 20 ml of freshly prepared Muller-Hinton agar (Merck, Cat.
No 5337), which was kept liquid at 50.degree. C., and to which 10% by
volume of the particular active substance solution was added. The samples
are readily soluble in DMSO. In each case 10.0 mg were dissolved in 10.0
ml of DMSO and further diluted with sterile double-distilled water. The
final concentrations after mixing with the test agar are to be found in
Table 2. Plates with the highest solvent concentration in each case
(control C 1) and with 10% double-distilled water (control C 2) without
active substance were used to check growth by comparison.
After solidification and drying (about 1 h at 37.degree. C.) the test
plates were inoculated by dotting with 10 .mu.l of the test organism
suspensions (inoculum) in each case.
The inocula were prepared in accordance with NCCLS/FDA recommendations.
After culturing on solid media and checking purity and identity, some
colonies were transferred into sterile Muller-Hinton broth (Merck, Cat.
No. 10293) and incubated until turbidity was visible. These cultures were
diluted by adding sterile broth until the turbidity corresponded to 0.5 of
the McFarland standard (=about 10(8) CFU/ml). A further 1:10 dilution was
used as inoculum, and its organism concentration was determined in
parallel once again by spiralometer.
The inoculated plates were incubated at 36.degree..+-.1.degree. C.
(bacteria) or 20.degree..+-.1.degree. C. (fungi) for 24 (bacteria) or 72
(fungi) h and then evaluated.
The complete test was repeated in an independent experiment. The results
were reproducible in all cases.
The reported MIC was that concentration of active substance at which no
growth was visible on inspection. Minimal, scarcely visible growth or a
few small colonies were not counted. On the growth controls without active
substance all the test organisms had grown as a spot about 0.5 cm.sup.2 in
size (precondition for evaluation). The following test organisms were
tested as examples (concentration in CFU/ml):
Staphylococcus (S.) aureus ATCC 6538 (1.2.times.10.sup.6)
Pseudomonas (Ps.) aeruginosa ATCC 27853 (1.0.times.10.sup.6)
Escherichia (E.) coli ATCC 8739 (1.4.times.10.sup.6)
Candida (C.) tropicalis DSM 4238 (0.8.times.10.sup.6)
Aspergillus (A.) niger ATCC 16404 (0.9.times.10.sup.6)
Microsporum (M.) canis CBS 38564 (1.0.times.10.sup.6)
Trichophyton (T.) mentagrophytes CBS 26379 (0.9.times.10.sup.6)
T. rubrum DSM 4167 (1.3.times.10.sup.6)
Epidermophyton (E.) floccosum CBS 55384 (1.4.times.10.sup.6)
TABLE 2
__________________________________________________________________________
Results of the agar dilution tests
Growth of test organisms: + MIC in .mu.g/ml
No growth of test organisms: -
C = controls without active substance
Compound of Example No.
Example No.
Test organisms
C 1
C 2
1 2 3 7 8 9 10 11 12 13 14 15 16 17 18 19
__________________________________________________________________________
S. aureus
+ + >5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
Ps. aeruginosa
+ + >5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
E. coli + + >5.0
>5.0
> 5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
>5.0
C. tropicalis
+ + 0.1
0.1
0.5
0.1
0.5
0.1
0.1
0.1
0.1
0.5
0.1
0.5
0.5
0.5
0.1
0.1
A. niger + + 0.1
0.1
0.1
0.1
0.5
0.5
0.5
1.0
0.5
0.5
0.1
0.5
0.5
0.5
1.0
0.5
M. canis + + 5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
>5.0
5.0
5.0
5.0
5.0
T. mentagrophytes
+ + 5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
>5.0
5.0
5.0
5.0
5.0
T. rubrum
+ + 5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
>5.0
5.0
5.0
5.0
5.0
E. floccosum
+ + 5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
5.0
>5.0
5.0
5.0
5.0
5.0
__________________________________________________________________________
The compounds of the present invention also have good inhibitory effects on
the test organisms Exophiola jennselmei.
For example:
______________________________________
Compound of
Example No. MIC [.mu.g/ml]
______________________________________
1 10
3 30
8 10
10 10
16 3
17 3
19 10
______________________________________
In the model of guinea pig trichophytosis (Trichophyton mentagrophytes),
cf. Heffter-Heubner: Handbuch der exp. Pharmakologie, Vol. XVI/II A, the
novel compounds are highly effective on external use without recurrence.
The actions of the test substances on topical use against Exophiola
jennselmei as the cause of subcutaneous mycoses and in a model of
experimental C. albicans vaginitis were likewise good.
The novel compounds also have oral activity. Good cure rates for infections
were obtained after oral administration of low therapeutic doses of the
test substances in the model of experimental generalized candidiasis in
mice and in the model of experimental vaginitis with Candida albicans in
rats.
The compounds are therefore particularly suitable for external as well as
oral treatment of fungal infections in humans and animals. Examples of
indications for humans and animals are: subcutaneous mycoses and
dermatomycoses, especially caused by dermatophytes such as species of the
genera Epidermophyton, Microsporum or Trichophyton, yeasts such as species
of the genera Candida and molds such as species of the genera Aspergillus,
Mucor or Absidia.
The compounds can be used alone or together with other known active
substances, especially antibiotics.
The chemotherapeutic agents or formulations are produced with conventional
solid, semi-solid or liquid excipients or diluents and the conventional
pharmaceutical auxiliaries appropriate for the required mode of
administration in a dosage suitable for use in a conventional manner,
especially by mixing (cf. H. Sucker et al., Pharmazeutische Technologie,
Thieme-Verlag, Stuttgart, 1978).
Examples of suitable dosage forms are uncoated and coated tablets,
capsules, pills, aqueous solutions, suspensions and emulsions, sterile
injectable solutions, non-aqueous emulsions, suspensions and solutions,
ointments, creams, pastes, lotions etc.
The therapeutically active compound is preferably present in pharmaceutical
formulations in a concentration of 0.01 to 90% by weight of the complete
mixture.
In general, on oral administration both in human and in veterinary
medicine, the active substance or substances can be administered in
amounts of from about 1.0 to about 50.0, preferably from 2 to 10, mg/kg of
body weight per day, preferably in the form of several individual doses to
achieve the required results. However, it may be necessary to deviate from
the stated dosages, specifically depending on the nature and severity of
the disease, the nature of the formulation and of the administration of
the drug, and the time or interval over which administration takes place.
Thus, in some cases less than the abovementioned amounts of active
substances may suffice, whereas in other cases these amounts must be
exceeded. Examples of pharmaceutical formulations:
EXAMPLE A
Tablet containing 250 mg of active substance Composition for 1,000 tablets:
______________________________________
Active substance 250 g
Potato starch 100 g
Lactose 50 g
4% gelatin solution 45 g
Talc 10 g
______________________________________
Production:
The finely powdered active substance, potato starch and lactose are mixed.
The mixture is moistened with about 45 g of 4% gelatin solution,
granulated and dried. The dried granules are screened, mixed with 10 g of
talc and compressed to tablets in a rotary tableting machine. The tablets
are packed in tightly closing polypropylene containers.
EXAMPLE B
Cream containing 1% active substance
______________________________________
Active substance 1.0 g
Glycerol monostearate 10.0 g
Cetyl alcohol 4.0 g
Polyethylene glycol 400 stearate
10.0 g
Polyethylene glycol sorbitan monostearate
10.0 g
Propylene glycol 6.0 g
Methyl p-hydroxybenzoate 0.2 g
Demineralized water to 100.0 g
______________________________________
Production:
The very finely powdered active substance is suspended in propylene glycol,
and the suspension is stirred into a melt of glycerol monostearate, cetyl
alcohol, polyethylene glycol 400 stearate and polyethylene glycol sorbitan
monostearate at 65.degree. C. A solution of the methyl p-hydroxybenzoate
in water at 70.degree. C. is emulsified in this mixture. After cooling,
the cream is homogenized in a colloid mill and packed into tubes.
EXAMPLE C
Dusting powder containing 1% active substance
______________________________________
Active substance 1.0 g
Zinc oxide 10.0 g
Magnesium oxide 10.0 g
Highly disperse silica 2.5 g
Magnesium stearate 1.0 g
Talc 75.5 g
______________________________________
Production:
The active substance is micronized in an air jet mill and mixed
homogeneously with the other ingredients. The mixture is passed through a
screen (mesh No. 7) and packed in polyethylene containers with perforated
cap.
Top